• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

Gilead Sciences shares soar; analysts lift targets on HIV strength and Yeztugo outlook

by August 9, 2025
by August 9, 2025

Gilead Sciences’ stock surged more than 8% on Friday, as its latest earnings drew the consensus from Wall Street that the company’s HIV franchise is not only holding firm but expanding, with its new prevention drug Yeztugo poised to be a catalyst for future growth.

Analysts from leading firms upgraded their price targets and reiterated bullish calls after the biopharmaceutical company posted steady second-quarter results and raised its 2025 guidance.

The stock surged more than 8% on Friday, extending gains after Gilead reported adjusted earnings per share of $2.01, slightly ahead of the $1.97 expected by analysts, according to LSEG.

Revenue rose 2% year-over-year to $7.1 billion, matching market forecasts.

Street applauds clean beat and raise

BMO Capital Markets described the quarter as “a breath of fresh air with a clean beat and raise,” noting the HIV business was “firing on all cylinders.”

The firm maintained its ‘Outperform’ rating and $130 price target.

Morgan Stanley went further, lifting its target to $143 from $135 while keeping an Overweight rating, citing “strong performance in the HIV segment” and the promising trajectory of Yeztugo.

J.P. Morgan (‘Overweight’, PT: $135) highlighted the company’s “confident” commentary on the launch, suggesting encouraging early adoption trends.

Bernstein (‘Outperform’, PT: $120) called the US PrEP market “ripe” for Yeztugo’s success, while Oppenheimer (‘Outperform’, PT: $128) pointed to the timing of the launch coinciding with a favourable US Supreme Court ruling that requires health insurers to cover certain recommended preventive services at no cost.

Twice-yearly PrEP drug seen as competitive edge

Yeztugo, approved by US regulators in June, is the first long-acting injectable for HIV prevention administered just twice a year.

Analysts say it addresses longstanding barriers to daily oral PrEP, such as adherence issues, stigma, and limited healthcare access.

CEO Daniel O’Day told Reuters that the drug’s rollout began almost immediately after approval.

“The first scrip was written within hours … the first dose was delivered within days,” he said, adding Gilead is on track to achieve its stated goal of 75% US insurer coverage of the twice-yearly injection within six months and 90% coverage within a year.

Total HIV product sales rose 7% year-over-year to $5.1 billion in the quarter, a figure analysts believe underscores the segment’s resilience despite generic competition for older products like Truvada.

Guidance upgrade fuels optimism

Gilead now expects full-year adjusted earnings of $7.95 to $8.25 per share, up from $7.70 to $8.10, and raised its 2025 product sales outlook to between $28.3 billion and $28.7 billion.

Chief Financial Officer Andrew Dickinson credited “strong HIV sales and continued expense discipline” for the upgrade.

Analysts at Zacks said, “It has been an eventful year for GILD so far. The recent FDA approval of lenacapavir under the brand name Yeztugo solidifies GILD’s HIV portfolio as its other prevention drug, Truvada, faces generic competition.”

While competitive pressures remain — and Gilead’s cell therapy business continues to face headwinds — the consensus view is that the company’s strengthened HIV franchise and disciplined execution have positioned it to navigate industry challenges and capture meaningful growth in the years ahead.

The post Gilead Sciences shares soar; analysts lift targets on HIV strength and Yeztugo outlook appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Natera shares surge 17% after strong Q2 results and upgraded guidance
next post
UBS strategist warns market rally may stall in August as US growth slows

Related Posts

OpenAI valuation hits $500 billion as employees sell...

October 2, 2025

Here’s why JPMorgan, Morningstar are bullish on Alibaba...

October 2, 2025

Europe markets open: Stoxx 600 jumps 0.6%, led...

October 2, 2025

Will the Tesco share price hit 500p as...

October 2, 2025

Tesco lifts profit forecast as summer, price cuts,...

October 2, 2025

Chinese carmakers expand hybrid sales in Europe as...

October 2, 2025

Hackers exploit Oracle systems, executives hit with ransom...

October 2, 2025

US digest: TrumpRx launch, job data, and government...

October 1, 2025

Asian markets: Nikkei sinks 1.16%, Sensex muted ahead...

October 1, 2025

Morning brief: Asian factory data splits on US...

October 1, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • Wiliot and Walmart Partner to Transform Retail with Ambient IoT and AI

    October 2, 2025
  • Manual trades embracing IoT for safer workplaces

    October 2, 2025
  • Soracom and Skylo Roll Out Integrated Satellite IoT

    October 2, 2025
  • Mission Creep: The Fed’s Foray Into State and Local Debt

    October 2, 2025
  • I Was a Victim of Cancel Culture. Don’t Perpetuate It.

    October 2, 2025
  • OpenAI valuation hits $500 billion as employees sell $6.6 billion in shares

    October 2, 2025

Editors’ Picks

  • 1

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 2

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025
  • 5

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 6

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025
  • 7

    Pop Mart reports 188% profit surge, plans aggressive global expansion

    March 26, 2025

Categories

  • Economy (2,758)
  • Editor's Pick (279)
  • Investing (185)
  • Stock (1,879)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

Nvidia’s Jensen Huang calls TSMC stock buyers...

August 22, 2025

US H-1B visa fee applies only to...

September 22, 2025

Here’s why the real reason IVV, VOO,...

March 22, 2025